A new open ECoG dataset highlights why long-term stability, not first implants, is becoming a key constraint in BCIs. Longevity reframes how progress and clinical value are judged.

Merge Labs launches with $250M in funding to pursue non-implant, ultrasound-based BCIs. The move contrasts with capital clustering around invasive platforms and reframes where early BCI risk is being underwritten.

Neurable has momentum, with new consumer EEG products, a $35m Series A, and a CES gaming prototype. The key question is whether EEG headphones can become a lasting daily habit rather than a novelty.

The UK is aligning ARIA funding, Cambridge NeuroWorks, and NHS reforms to advance non-invasive neurotech, closing the early-stage innovation gap and using national health infrastructure to validate and scale wearables.

Elon Musk says Neuralink will scale implants and automate brain surgery by 2026. The claim raises questions about how invasive BCIs fit clinical, financial, and patient realities.

Northwestern’s wireless micro-LED implant writes patterned light signals into cortex, showing optogenetics as a potential input channel and outlining what still blocks products.

Given this mix of acceleration and backlash, it’s worth asking a simple question: are BCIs still overhyped, and if so, where exactly is the gap between story and reality?

A new entrant is forming in the brain–computer interface space with unusually deep capital, strong AI ties, and ambitions that may extend beyond medicine, adding a fresh dynamic to an already competitive neurotech field.

Most wearables infer how we feel from the body. A new class of consumer neurotechnology instead measures the brain directly, offering a window into attention, fatigue, and cognitive load during everyday work.

Parkinson’s disease unfolds continuously, yet care remains episodic. By turning everyday wearables into sources of clinical signal, a new approach is emerging that reframes how neurological disease is measured, tracked, and managed.

A new generation of brain–computer interfaces is emerging with a different philosophy: minimise invasiveness, prioritise safety, and fit real clinical workflows. Precision Neuroscience exemplifies this shift toward practical neurotechnology.